Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

InnoCare Launches Early Access to CD19 Immunotherapy in China for B-cell Lymphoma

publication date: Jan 22, 2024

Beijing InnoCare has been approved to launch tafasitamab (Minjuvi®) under an early access program to treat patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab, a CD19 targeting immunotherapy, will be administered in combination with lenalidomide and will be available in the Guangdong-Hong Kong-Macao Greater Bay Area. InnoCare has completed patient enrollment in a China registrational trial of the combination therapy, and it expects to submit the biologics license application (BLA) in the second quarter of 2024. More details....

Stock Symbols: (HK: 09969; SHA: 688428)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital